A Third Proof-of-Concept Study to Evaluate the Efficacy of NOBO, a Novel Postbiotic, in Controlling Axillary Odor in Healthy Adults

Conditions

• Body Odor

Eligibility Criteria

Sex

ALL

Age

18 Years - 70 Years

Healthy Volunteers

Accepted

Interventions

• NOBO postbiotic — OTHER
  The active ingredient in the NOBO deodorant is a yeast-based fermentation product (postbiotic) of the Starmerella genus.
• Placebo — OTHER
  The placebo deodorant is composed of 10% ethanol in water

Study Details

The goal of this clinical trial is to evaluate the performance of NOBO, a yeast-based fermentation product (postbiotic) designed to control axillary odor, in controlling axillary odor in healthy male and female adults age 18 - 70 with confirmed self-perception of body odor. The main question it aims to answer is: Does NOBO decrease self-perceived odor of the intervention axilla compared to the placebo axilla at any time point? Researchers will compare the intervention axilla odor score to the placebo axilla odor score to see if there is a difference in self-perceived odor. Participants will: * be given a NOBO deodorant spray and a placebo deodorant spray (each assigned to one axilla) * self assess body odor * self assess skin irritation

Key Dates

First listed

Jul 24, 2026

Start date

Jul 27, 2026

Status verified

Jul 2026

Primary completion

Jul 31, 2026

Completion

Jul 31, 2026

Study Design

Enrollment

14 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: NOBO deodorant
  The NOBO deodorant is composed of ≤2.6% yeast fermentation product and 10% ethanol in water. A dose is 0.48 mL per axilla for female subjects (3 actuations) or 0.64 mL per axilla for male subjects (4 actuations), delivered twice a day.
• Placebo Comparator: Placebo deodorant
  The placebo deodorant is composed of 10% ethanol in water. The placebo deodorant contains the same concentration of ethanol as the NOBO deodorant. A dose is 0.48 mL per axilla for female subjects (3 actuations) or 0.64 mL per axilla for male subjects (4 actuations), delivered twice a day.

Primary Outcome Measure

Axillary odor self assessment (comparative) [ Time Frame: At baseline (before application), immediately after first application, Day 1 PM, Day 2 PM, and Day 3 PM ]

Locations (1)

Find similar trials in Brooklyn, NY